<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04134468</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC10219</org_study_id>
    <secondary_id>IRB833642</secondary_id>
    <nct_id>NCT04134468</nct_id>
  </id_info>
  <brief_title>MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma</brief_title>
  <official_title>UPCC 10219: Phase II Study Of Stromal Changes Detected By DCE- and DW-MRI In Response To PEGPH20 Combined With Chemotherapy In Subjects With Locally-Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Halozyme Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is being conducted to determine the effects of PEGPH20 plus chemotherapy&#xD;
      treatment on the MRI characteristics of locally advanced pancreatic cancer patient tumors.&#xD;
      Subjects will received Gemcitabine, Abraxane and PEGPH20.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Halozyme halted development of PEGPH20 following Phase 3 failure.&#xD;
  </why_stopped>
  <start_date type="Anticipated">January 2020</start_date>
  <completion_date type="Anticipated">November 11, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 11, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in lesion size</measure>
    <time_frame>baseline and 4 months</time_frame>
    <description>Change in lesion size</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving a complete R0 surgical resection</measure>
    <time_frame>at time of surgery</time_frame>
    <description>Proportion of patients achieving a complete R0 surgical resection</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Pancreatic Ductal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Pegvorhyaluronidase alfa plus Abraxane and Gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pegvorhyaluronidase alfa 3ug/kg IV twice weekly during Cycle 1 and then weekly on days of chemotherapy during Cycles 2-4. Abraxane 125mg/m2 IV and Gemcitabine 1000mg/m2 IV on Day 1, 8, 15 of Cycles 1-4. All cycles will be 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegvorhyaluronidase alfa</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Pegvorhyaluronidase alfa plus Abraxane and Gemcitabine</arm_group_label>
    <other_name>PEGPH20</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abraxane</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Pegvorhyaluronidase alfa plus Abraxane and Gemcitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Pegvorhyaluronidase alfa plus Abraxane and Gemcitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed Informed Consent Form&#xD;
&#xD;
          2. Capable of giving informed consent.&#xD;
&#xD;
          3. Ability and willingness to comply with the protocol including all scheduled MRI&#xD;
             studies and paired tumor biopsies&#xD;
&#xD;
          4. Aged â‰¥ 18 years.&#xD;
&#xD;
          5. borderline or unresectable pancreatic adenocarcinoma without distant metastatic&#xD;
             disease.&#xD;
&#xD;
          6. ECOG PS of 0 or 1&#xD;
&#xD;
          7. Must have adequate organ and hematopoietic function&#xD;
&#xD;
          8. Female and Males must use an approved contraceptive method&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Received prior therapy for pancreatic adenocarcinoma&#xD;
&#xD;
          2. History of deep vein thrombosis (DVT) or pulmonary embolism (PE)&#xD;
&#xD;
          3. Contraindication to therapeutic anticoagulation or heparin&#xD;
&#xD;
          4. Intolerance to dexamethasone&#xD;
&#xD;
          5. Contraindication to MRI or unwillingness to undergo all scheduled MRI exams&#xD;
&#xD;
          6. Known or suspected brain metastasis&#xD;
&#xD;
          7. Significant cardiovascular disease such as current New York Heart Associate Class&#xD;
             III/IV heart failure, myocardial infarction or stroke within 6 months prior to&#xD;
             enrollment&#xD;
&#xD;
          8. A second primary malignancy that, in the judgment of the investigator, may affect the&#xD;
             interpretation of results&#xD;
&#xD;
          9. Any illness or condition that in the opinion of the investigator may affect the safety&#xD;
             of the subject or the evaluation of any study endpoint&#xD;
&#xD;
         10. Active bacterial or fungal infection requiring IV therapy at the start of protocol&#xD;
             treatment&#xD;
&#xD;
         11. Subjects may not receive concomitant anticancer agents or radiation.&#xD;
&#xD;
         12. Female subjects who are pregnant or nursing&#xD;
&#xD;
         13. Pre-existing peripheral neuropathy &gt; CTCAE Grade 2.&#xD;
&#xD;
         14. Known allergy to hyaluronidase&#xD;
&#xD;
         15. Current use of megestrol acetate (use within 10 days of Day 1)&#xD;
&#xD;
         16. Inability to comply with study and follow-up procedures as judged by the Investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Karasic, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abramson Cancer Center at University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 18, 2019</study_first_submitted>
  <study_first_submitted_qc>October 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2019</study_first_posted>
  <last_update_submitted>January 30, 2020</last_update_submitted>
  <last_update_submitted_qc>January 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

